Q-omics provides the consensus-scored TOP1MT profile across patient tissues and cancer cell-line models. TOP1MT expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TOP1MT is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TOP1MT RNA expression shows 17,500 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where TOP1MT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TOP1MT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TOP1MT survival associations across molecular data types. TOP1MT RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TOP1MT RNA expression–survival associations across cancer types. High TOP1MT expression shows unfavorable associations in LIHC, ACC, UCS, KICH, HNSC and KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TOP1MT RNA expression.
This table summarizes TOP1MT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TOP1MT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TOP1MT shows higher tumor expression in HNSC, COAD, BLCA, KIRC, STAD and LUAD. The HNSC box plot shows higher TOP1MT RNA expression in tumor versus normal tissue (log2 FC = +1.414, t-test p < 0.001).
This table shows molecular features associated with TOP1MT in patient tissues and cancer cell lines. In patient samples, TOP1MT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TOP1MT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
